Facility Capabilities

Our Clinical Trial Area lyophilizer is equipped with CIP and SIP precise cold shelf loading at -45°C and room dehumidification. We maintain product integrity throughout the lyophilization process.

Our facility can handle vial sizes ranging from small to large, providing versatility for various applications. Rest assured, our protected and isolated RAID 5 PC guarantees increased data reliability and performance.

Commercial Lyophilization

JHS can handle your lyophilization projects: from clinical to commercial sized batches.

  • Automated CIP, SIP, and Vial (un)loading
  • Process up to 165 vials/minute
  • -45°C cold shelf loading
Lyo Capacity

Lyo Capacity

Currently, JHS has 8 lyophilizers ready for production-use, with another available in 2025. In 2026, two additional lyophilizers will be qualified as part of our ongoing expansion project.

 

Shelf Space
Vial Size
Batch Size
115 - 400 ft2
2 mL - 100 mL
Up to 153,000
Clinical Trial Lyophilization

Clinical Trial Lyophilization

Freeze-dry your clinical trial project with our clinical trial lyophilizer, specifically suited for small lots.

  • Automated CIP, SIP, and Vial (un)loading
  • External condenser
  • -45°C cold shelf loading
Shelf Space
Vial Size
Batch Size
30 ft2
Up to 5 mL
Up to 4,500

Stay Up to Date with JHS

Expediting Cold Chain Supply Resources
A COVID-19 therapeutic product required a very large quantity of compounding materials to be stored under refrigerated conditions. The need was far greater than JHS’ existing capacity for cold storage given the scale of the pandemic.
Adapting Equipment to Keep Pace with Demand
JHS applied innovative thinking. They rapidly identified alternatives, such as previously owned equipment that could adapt and qualify for manufacturing. JHS project managers and the tech transfer team also designed alternative solutions.
Ocugen Secures Manufacturing Partnership
Ocugen, Inc. a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, announced that it has entered into an agreement with Jubilant HollisterStier of Spokane, Washington for manufacturing of vaccine candidate COVAXIN® for the US and Canadian markets.

Begin the Manufacturing Process Now

Contact us today to partner with JHS on your next manufacturing project.